Medtech Trends 2026: Market & Industry Insights

Executive Summary

The medical technology (medtech) sector enters 2026 amid structural shifts that are redefining market economics, care delivery, manufacturing footprints, and competitive dynamics. According to Clarivate's *Medtech Trends to Watch 2026*, five forces deserve particular attention: the expansion of China's volume-based procurement (VBP), the migration of procedures to outpatient and ambulatory surgical centers (ASCs), global supply chain pressures, the clinical and commercial impact of GLP-1 receptor agonists, and the rise of platform-based competition enabled by robotics, imaging, navigation, and digital workflows.

For finance executives, accountants, auditors, and investors, these trends are not merely operational issues. They carry significant implications for revenue recognition, cost structures, asset valuations, impairment testing, tax planning, disclosure requirements, and corporate governance. This article examines each trend from a financial and governance perspective, highlighting the accounting challenges and strategic decisions likely to shape medtech companies' performance and long-term sustainability.

Introduction

Medtech companies have long navigated regulatory complexity and reimbursement uncertainty. Yet the convergence of pricing reform, site-of-care evolution, geopolitical trade tensions, metabolic disease management, and digital convergence presents a uniquely complex environment. The Clarivate analysis provides a data-driven foundation for understanding these market shifts. This article builds on that foundation to explore the financial reporting, capital allocation, and governance implications for stakeholders across the global medtech ecosystem.

Financial Context

The global medtech market is substantial, with growth driven by aging populations, chronic disease prevalence, and technological innovation. However, pricing pressure from public and private payers, along with rising input costs, is compressing margins. In this environment, accurate financial reporting and robust internal controls become critical for maintaining investor confidence and access to capital.

Main Analysis

1. Mainland China's VBP expansion: pricing compression and asset valuation

Mainland China's national volume-based procurement program has evolved from a patient-access initiative into a market-structuring mechanism. The newest rules introduce more sophisticated anchor-price logic and allocation systems favoring domestic manufacturers. For multinational medtech companies, VBP participation often means steep price reductions in exchange for volume guarantees.

Financial reporting implications: Companies must evaluate whether price concessions impair the recoverability of long-lived assets, including property, plant, equipment, and capitalized intangible assets. Impairment testing requires estimates of future cash flows, discount rates, and long-term growth rates—all of which become more uncertain under VBP. Additionally, revenue recognition may be affected if VBP contracts include variable consideration, rebates, or performance obligations that span multiple years.

Transfer pricing and tax: VBP-driven price changes may necessitate transfer pricing adjustments between manufacturing entities, distribution hubs, and local subsidiaries. Tax teams should assess the arm's-length nature of intercompany transactions and document economic substance to avoid disputes with tax authorities.

Disclosure: Management should consider expanding segment disclosures and geographic concentration risk, particularly if Chinese revenues represent a material portion of total revenue. The SEC and other regulators may scrutinize forward-looking statements about pricing and volume expectations.

2. Outpatient and ASC settings: changing customer mix and economic value

CMS's 2026 OPPS and ASC Payment System Final Rule expands the ASC Covered Procedure List and phases out the inpatient-only list. Higher-acuity procedures, such as cardiac ablation, are increasingly eligible for lower-cost outpatient settings.

Financial implications: The shift in site of care alters the customer base from hospitals to ASCs, which may have different purchasing behaviors, payment terms, and bargaining power. Companies must adapt their sales commission models, distribution agreements, and after-sale support structures. For accounting purposes, changes in customer contracts may affect the timing and pattern of revenue recognition.

Product cost and pricing: Devices designed for ASC settings may require different packaging, sterilization, or training, affecting cost of goods sold. Pricing strategies must reflect the economic value of shorter procedure times and reduced facility costs, which may support premium pricing despite overall cost pressures.

Asset utilization: Manufacturers may need to rebalance inventory and distribution networks to serve ASCs efficiently. This could lead to inventory write-downs or supply chain reconfiguration costs.

3. Global trade and supply chain pressures: cost volatility and resilience

Tariff exposure, geopolitical factors, and fluctuating material costs are challenging medtech production assumptions. Companies are diversifying sourcing and pursuing multi-region manufacturing footprints.

Accounting implications: Tariffs and freight costs are period costs that flow through cost of sales. Companies may need to assess whether inventory carrying values exceed net realizable value, particularly if tariffs raise landed costs. Long-term supply contracts may need to be assessed for onerous contract provisions under IFRS or ASC.

Hedging and foreign exchange: Currency volatility and commodity price fluctuations may prompt companies to use derivatives. Hedge accounting under IFRS 9 or ASC 815 requires rigorous documentation and effectiveness testing. Finance teams should ensure systems can capture hedge relationships accurately.

Restructuring: Manufacturing footprint rationalization may trigger restructuring charges, severance, and asset impairments. Companies should develop formal restructuring plans to meet recognition criteria under IAS 37 or ASC 420.

ESG and sustainability: Supply chain resilience is increasingly tied to environmental, social, and governance (ESG) disclosures. Investors expect transparency around supplier concentration, human rights, and carbon emissions. This adds to the burden of data collection and assurance readiness.

4. GLP-1 therapies: demand shifts and portfolio rebalancing

GLP-1 receptor agonists are reshaping metabolic disease management, affecting bariatric surgery volumes and related device markets. Downstream effects span diabetes care, sleep apnea, and cardiovascular monitoring.

Financial impact: A reduction in bariatric procedure volumes could impair goodwill and intangible assets associated with acquired bariatrics-focused businesses. Companies should conduct impairment tests at the cash-generating unit level. Conversely, increased demand for continuous glucose monitors, cardiovascular devices, and sleep apnea equipment may create growth opportunities.

R&D and capitalization: Companies may need to reallocate R&D spending away from bariatric devices and toward areas aligned with GLP-1's ripple effects. Capitalized development costs under IAS 38 or ASC 985 should be assessed for technological feasibility and future economic benefits. Changes in project viability may require write-offs.

Revenue forecasting: Volatility in procedure volumes makes revenue forecasting difficult. Companies should provide robust sensitivity analyses in management discussion and analysis (MD&A) to help investors understand potential outcomes.

5. Enabling technologies and platform-based competition: business model transformation

Robotics, imaging, navigation, and digital workflow software are converging into integrated platforms. Companies are investing in ecosystems that support clinical planning, surgical execution, and postoperative care.

Accounting for software: Significant judgment is required to determine whether software development costs should be capitalized or expensed. Under IFRS, internally generated intangible assets are capitalized only when certain criteria are met. For U.S. GAAP, the guidance for internal-use software (ASC 350-40) has different thresholds. Companies may need to separate project stages and document efforts carefully.

Revenue recognition: Platform solutions often combine hardware, software, services, and data analytics. Identifying performance obligations and allocating transaction price requires detailed analysis under IFRS 15/ASC 606. Subscriptions and usage-based fees may give rise to deferred revenue and contract liabilities.

Data monetization: As platforms generate real-world data, companies may monetize de-identified information. This raises privacy and cybersecurity governance questions. Financial reporting must reflect any net proceeds from data arrangements, and legal teams must ensure compliance with GDPR and other regulations.

Corporate governance: Platform strategies demand robust board oversight of cybersecurity, data governance, and AI ethics. Audit committees should understand how algorithmic outputs affect clinical outcomes and financial reporting.

Business & Market Impact

These trends affect medtech companies' financial performance in several ways:

Capital allocation: Executives must prioritize investments in resilient supply chains, digital platforms, and growth areas such as ASC-focused products and metabolic disease technologies. M&A strategies may shift toward bolt-on acquisitions that fill gaps.
Investor communication: Clear disclosure of pricing risks, supply chain mitigation, and product lifecycle changes will be essential to maintain investor confidence. Companies that proactively address these issues may command lower risk premiums.
Credit risk: Rating agencies will scrutinize leverage, liquidity, and the ability to sustain margins in a deflationary pricing environment. Supply chain diversification may increase capital expenditures, affecting free cash flow.
Tax and legal: Transfer pricing, customs valuation, and tax incentives for reshoring are key considerations.

Governance Insights

Boards should ensure that risk management frameworks capture the interdependencies among pricing reform, trade policy, and technology disruption. Specific areas for board attention include:

Pricing governance: Establish a cross-functional pricing committee that includes finance, legal, and commercial leaders to assess VBP and payer negotiations.
Supply chain oversight: Review concentration risk and develop contingency plans. Ensure that supply chain data is auditable and that internal controls over inventory valuation are robust.
Cybersecurity: Platform-based business models increase cyber risk. Boards should mandate regular penetration testing and alignment between cybersecurity framework and financial reporting controls.
Disclosure controls: As new revenue streams and risks emerge, companies should update disclosure controls and procedures to capture material changes.

Future Outlook

Over the next 3–10 years, medtech companies will likely see:

Increased use of artificial intelligence in pricing, demand forecasting, and clinical decision support, with corresponding challenges for model risk management and audit.
Digital accounting and real-time financial reporting could provide faster visibility into revenue trends and supply chain costs.
ESG reporting will become more standardized, with stronger assurance requirements. Carbon accounting may become material to medtech manufacturers' financial statements.
Regulatory frameworks will continue to evolve, potentially aligning more closely across jurisdictions. Companies that adopt robust internal controls and transparent reporting will be better positioned.

Conclusion

The medtech industry's structural shifts demand a finance function that is forward-looking and analytically rigorous. By understanding the financial implications of pricing reforms, site-of-care migration, supply chain pressures, GLP-1 disruption, and platform-based competition, CFOs and finance teams can support strategic decisions, maintain accurate reporting, and protect long-term shareholder value.

Key Takeaways

China's VBP expansion requires careful impairment testing and transfer pricing documentation.
The shift to ASCs changes revenue recognition, cost structures, and customer mix.
Supply chain pressures demand robust inventory valuation, hedging, and restructuring plans.
GLP-1 therapies may necessitate portfolio rebalancing and asset impairment assessments.
Platform-based competition raises complex questions around software capitalization and revenue recognition.
Boards must integrate pricing, supply chain, cybersecurity, and disclosure risks into governance frameworks.

Sources

Clarivate: "5 medtech trends to watch in 2026" – https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026